Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
RECORDATI GROUP · Post-Bariatric Hypoglycemia
Phase 2
Active, not recruiting
93
2025-09
Industry sponsor intelligence
RECORDATI GROUPClinical Pipeline.
Lead-sponsor view of RECORDATI GROUP's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 4
- Recruiting
- 0
- Active
- 1
- Completed
- 3
- Results posted
- 2
- Avg enrollment
- 157
Pipeline overview
Programs by phase and activity.
Velocity
RECORDATI GROUP trials by start year
Study start year · indexed snapshot
Development
Trials by phase
3phase labels
Early Phase 10
Phase 11
Phase 21
Phase 30
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Pasireotide → | 4 | 1 | 1 | 0 | 1 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
RECORDATI GROUP · Pharmacokinetics · Safety
Phase 1
Completed
40
2026-02
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
RECORDATI GROUP · Cushings Disease
Not applicable
Completed
152
2024-10
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP · Cushing's Disease · Acromegaly
Phase 4
Completed
337
2024-10
Search sponsor records
All RECORDATI GROUP studies.
This page groups studies where RECORDATI GROUP is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
4 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07312643Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an AmpuleFeb 4, 2026NCT05928390Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaSep 22, 2025NCT02310269Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseOct 15, 2024NCT01794793Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesOct 1, 2024